Afrezza Approval Comes With Post-Marketing Trial On Lung Cancer, CV Risk
Executive Summary
FDA’s unusually specific request suggests continued worries about safety of MannKind’s inhalable insulin; large trial (8,000-10,000 type 2 diabetics) has a variety of goals.